Report #2840682

Received May 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: LA
Recovered: Unknown
Vaccinated: Jan 29, 2025
Onset: Feb 4, 2025
Days to onset: 6
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
UNK	VACCINE NOT SPECIFIED (NO BRAND NAME)	UNKNOWN MANUFACTURER	1	Y013009	OT / LA

Symptoms (2)

Injection site erythemaInjection site pruritus

Symptom narrative

INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; This spontaneous report was received from FDA and refers to an 81-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 29-Jan-2025, the patient was vaccinated with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (lot #Y013009, expiration date: 17-Nov-2025), dose number 1, administered by Intramuscular route in left arm for an unknown indication. On 04-Feb-2025, the patient experienced redness (injection site erythema) and itching (injection site pruritus) at injection site. At the reporting time, the outcome of the events was unknown. The causal relationship between the events and Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) was not provided.